Angelini Pharma's CSO Rafal Kaminski, underscores the rising burden of brain diseases, advocating global attention to brain health. The Headway initiative is presented as a collaborative platform promoting harmonization programs and European guidelines, emphasizing science's crucial role in evidence-based decision-making.
